Histamine H-3 receptor and cholinesterases as syne... - BV FAPESP
Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Histamine H-3 receptor and cholinesterases as synergistic targets for cognitive decline: Strategies to the rational design of multitarget ligands

Texto completo
Autor(es):
Lopes, Flavia B. [1] ; Aranha, Cecilia M. S. Q. [1] ; Fernandes, Joao Paulo S. [1]
Número total de Autores: 3
Afiliação do(s) autor(es):
[1] Univ Fed Sao Paulo, Dept Pharmaceut Sci, Campus Diadema, BR-09913030 Diadema - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo de Revisão
Fonte: CHEMICAL BIOLOGY & DRUG DESIGN; v. 98, n. 2, p. 212-225, AUG 2021.
Citações Web of Science: 0
Resumo

The role of histamine and acetylcholine in cognitive functions suggests that compounds able to increase both histaminergic and cholinergic neurotransmissions in the brain should be considered as promising therapeutic options. For this purpose, dual inhibitors of histamine H-3 receptors (H3R) and cholinesterases (ChEs) have been designed and assessed. In this context, this paper reviews the strategies used to obtain dual H3R/ChEs ligands using multitarget design approaches. Hybrid compounds designed by linking tacrine or flavonoid motifs to H3R antagonists were obtained with high affinity for both targets, and compounds designed by merging the H3R antagonist pharmacophore with known anticholinesterase molecules were also reported. These reports strongly suggest that key modifications in the lipophilic region (including a second basic group) seem to be a strategy to reach novel compounds, allied with longer linker groups to a basic region. Some compounds have already demonstrated efficacy in memory models, although the pharmacokinetic and toxicity profile should be considered when designing further compounds. In conclusion, the key features to be considered when designing novel H3R/ChEs inhibitors with improved pharmacological profile were herein summarized. (AU)

Processo FAPESP: 19/23696-7 - Síntese e avaliação da atividade anticolinesterásica de anilidoalquilpiperazinas: potenciais agentes multialvo
Beneficiário:Flávia Barrio Lopes
Modalidade de apoio: Bolsas no Brasil - Iniciação Científica